Get started
Author

A.Yu. Borozinets

Observed names: A. Yu. Borozinets, A. Yu. Borоzinets, A., Borozinets, AYu Borozinets, Anton Borozinets, Anton I. Borozinets, Anton Yu. Borozinets, А Borozinets, А. Yu. Borozinets, А.Ю. Борозинец, Борозинец Антон Юрьевич
ORCID: 0000-0002-4863-8471
Observed ORCID: 0000-0002-4863-8471
OpenAlex ID: A5069705379
Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy
2020 · V. V. Ptushkin, A. D. Kulagin, et al. · Terapevticheskii arkhiv · 36
PDF
Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers
2019 · S. B. Fitilev, A. V. Vozzhaev, et al. · Oncohematology · 6
Specificity of the Moroctocog Alpha Molecule: Results of a Prospective, Multicenter, Open-label, Observational Study of Efficacy and Safety in Children Aged 12 to 18 Years With Hemophilia a
2021 · V.V. Vdovin, M.V. Kosinova, et al. · PEDIATRIA Journal named after G N SPERANSKY · 3
Gaucher disease in children: what has changed in the 21st century
2020 · M. B. Belogurova, Yu. V. Dinikina, et al. · Russian Journal of Pediatric Hematology and Oncology · 3
PDF
Safety, tolerability, and pharmacokinetics of verenafusp alfa in healthy volunteers: results of an open-label multicohort phase I study
2026 · Elena A. Smolyarchuk, Susanna S. Sologova, et al. · Terapevticheskii arkhiv · 2
PDF
Results of Open, Prospective, Multicenter, Non-comparative Study of Nonacog Alpha Pharmacokinetics, Efficacy and Safety in Children Aged 2–12 Years With Severe and Moderate Hemophilia В
2022 · T.A. Andreeva, V.V. Lebedev, et al. · PEDIATRIA Journal named after G N SPERANSKY · 2
Interim results of a multicenter, open-label, multicohort study of enzyme replacement therapy with Verenafusp Alfa in patients under 18 years of age with Mucopolysaccharidosis Type II
2026 · L.S. Namazova-Baranova, N.D. Vashakmadze, et al. · PEDIATRIA Journal named after G N SPERANSKY · 1
Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology
2025 · A.A. Voskresenskaya, M.B. Sarkizova, et al. · Russian Annals of Ophthalmology · 1
Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease
2025 · Elena A. Lukina, Rodion V. Ponomarev, et al. · Terapevticheskii arkhiv · 1
Ethical aspects of clinical trials of blood clotting factors in children with hemophilia
2022 · DA Kudlay, VV Vdovin, et al. · Медицинская этика · 1
PDF
The clinical use and cost-effectiveness of domestic blood coagulation factors VIII and IX
2022 · D. S. Fokina, O. V. Zhukova, et al. · Pediatric Hematology/Oncology and Immunopathology · 1
PDF
Efficacy and Safety of Moroctocog Alfa in an Open, Multicenter, Prospective, Clinical Study in Children 2 to 6 Years of Age With Severe Hemophilia a
2021 · M.A. Timofeeva, V.V. Lebedev, et al. · PEDIATRIA Journal named after G N SPERANSKY · 1
Results of the Open Multicenter Prospective Clinical Study of the Efficacy, Safety, and Pharmacokinetics of Moroctocog Alpha in 6 to 12 Year Old Children With Hemophilia a
2021 · M.A. Timofeeva, T.A. Andreeva, et al. · PEDIATRIA Journal named after G N SPERANSKY · 1
Immunogenicity Study of the Russian Recombinant Activated Coagulation Factor Vii in Hemophilia a Patients With Inhibitors
2020 · T.A. Andreeva, V.Yu. Zorenko, et al. · PEDIATRIA Journal named after G N SPERANSKY · 1
Features of Development and Research of National Recombinant Drugs of Coagulation Factors Vii, Viii, Ix
2019 · I. Davydkin, V. Zorenko, et al. · Vrach · 1
The results of the use of Octofactor in patients with moderate and severe hemophilia A (data from a prospective, multicenter, open-label, observational study)
2019 · N. I. Zozulya, O. I. Yastrubinetskaya, et al. · Russian Journal of Pediatric Hematology and Oncology · 1
PDF
Efficiency and safety of Innonafactor in prevention of bleeding episodes in patients with severe and moderate hemophilia B: Results of part 1 of phase II-III clinical trial
2015 · T. A. Andreeva, V. Yu. Zorenko, et al. · Pediatric Hematology/Oncology and Immunopathology · 1
Results of a Prospective Multicenter Open-label Observational Study of Enzyme Replacement Therapy With an Imiglucerase Biosimilar in Children With Type 1 Gaucher Disease
2026 · G.B. Movsisyan, A.S. Potapov, et al. · PEDIATRIA Journal named after G N SPERANSKY
Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study
2026 · Oleg Kotenko, Natalia Kozlovskaya, et al. · The Nephron journals/Nephron journals
PDF
Supplementary Material for: Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study
2026 · karger, figshare admin, O., Kotenko, et al. · Figshare
Results of an open-label randomized crossover comparative study of the safety, pharmacodynamics and pharmacokinetics of romiplostim in healthy volunteers
2024 · А.Л. Вёрткин, Г.Ю. Кнорринг, et al. · Тромбоз гемостаз и реология
Dmitry A. Kudlay: 55th Anniversary
2023 · D.A. Kudlay, A.G. Rumyantsev, et al. · PEDIATRIA Journal named after G N SPERANSKY
Current application issues of modern technologies in the diagnosis and treatment of Gaucher disease
2022 · М.З. Гасанов, В.П. Терентьев, et al. · Тромбоз гемостаз и реология
Results of a prospective multicentre open observational study of nonacog alfa in patients with severe and moderate hemophilia B.
2022 · Н.И. Зозуля, А.Н. Мамаев, et al. · Тромбоз гемостаз и реология
About Awards and Conferment of Academic Titles to the Editorial Board Members of the Journal «pediatria. Journal Named After G.n. Speransky»
2022 · D.G. Zaridze, I.S. Stilidi, et al. · PEDIATRIA Journal named after G N SPERANSKY
Works count: 32
Citation count: 63
H-index: 3
I10-index: 1
Year
Topic
Type